Andressa Souza de Oliveira

Dr. Andressa Souza de Oliveira

Universidade de Brasília - UnB
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
LLLaís Flávia Nunes Lemes
Laís Flávia Nunes Lemes
GRGiselle de Andrade Ramos
Giselle de Andrade Ramos
AOAndressa Souza de Oliveira
Andressa Souza de Oliveira
FSFernanda Motta R. da Silva
Fernanda Motta R. da Silva
GCGina de Castro Couto
Gina de Castro Couto
LRLuiz Romeiro
Luiz Romeiro

29 March 2019 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
LRLuiz Romeiro
Luiz Romeiro
JNJéssica Larissa da Costa Nunes
Jéssica Larissa da Costa Nunes
CMCamila de Oliveira Miranda
Camila de Oliveira Miranda
GHGabriella Heyn
Gabriella Heyn
AOAndressa Souza de Oliveira
Andressa Souza de Oliveira
MBMaria Laura Bolognesi
Maria Laura Bolognesi

7 September 2021 in Molecules
Verified
Journal Article
Open access
PDF file
EUElisa Uliassi
Elisa Uliassi
AOAndressa Souza de Oliveira
Andressa Souza de Oliveira
LNLuciana de Camargo Nascente
Luciana de Camargo Nascente
LRLuiz Romeiro
Luiz Romeiro
MBMaria Laura Bolognesi
Maria Laura Bolognesi
Alzheimer’s disease (AD) is a complex neurodegenerative disorder with a multifaceted pathogenesis. This fact has long halted the development of effective anti-AD drugs. Recently, a therapeutic strategy based on the exploitation of Brazilian biodiversity was set with the aim of discovering new disease-modifying and safe drugs for AD. In this review, we will illustrate our efforts in developing new molecules derived from Brazilian cashew nut shell liquid (CNSL), a natural oil and a byproduct of cashew nut food processing, with a high content of phenolic lipids. The rational modification of their structures has emerged as a successful medicinal chemistry approach to the development of novel anti-AD lead candidates. The biological profile of the newly developed CNSL derivatives towards validated AD targets will be discussed together with the role of these molecular targets in the context of AD pathogenesis.

25 September 2024 in Molecular and Cellular Endocrinology
Verified
Journal Article
Closed access
AFAline Fernandes-Da-Silva
Aline Fernandes-Da-Silva
DSDaiana Araujo Santana-Oliveira
Daiana Araujo Santana-Oliveira
AOAndressa Souza de Oliveira
Andressa Souza de Oliveira
TFThaís A.M. Ferreira
Thaís A.M. Ferreira
NMNatália Cipriano Monteiro
Natália Cipriano Monteiro
VSVanessa Souza-Mello
Vanessa Souza-Mello

5 September 2024 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
AOAlicia Simalie Ombredane
Alicia Simalie Ombredane
NMNatália Ornelas Martins
Natália Ornelas Martins
GSGabriela Mara Vieira Souza
Gabriela Mara Vieira Souza
VAVictor Hugo Sousa Araujo
Victor Hugo Sousa Araujo
ISIsis Oliveira Szlachetka
Isis Oliveira Szlachetka
GJGraziella Joanitti
Graziella Joanitti
Combination therapy integrated with nanotechnology offers a promising alternative for breast cancer treatment. The inclusion of pequi oil, anacardic acid (AA), and docetaxel (DTX) in a nanoemulsion can amplify the antitumor effects of each molecule while reducing adverse effects. Therefore, the study aims to develop pequi oil-based nanoemulsions (PeNE) containing DTX (PDTX) or AA (PAA) and to evaluate their cytotoxicity against triple-negative breast cancer cells (4T1) in vitro. The PeNE without and with AA (PAA) and DTX (PDTX) were prepared by sonication and characterized by ZetaSizer® and electronic transmission microscopy. Viability testing and combination index (CI) were determined by MTT and Chou-Talalay methods, respectively. Flow cytometry was employed to investigate the effects of the formulations on cell structures. PeNE, PDTX, and PAA showed hydrodynamic diameter < 200 nm and a polydispersity index (PdI) of 0.3. The association PDTX + PAA induced a greater decrease in cell viability (~70%, p < 0.0001) and additive effect (CI < 1). In parallel, an association of the DTX + AA molecules led to antagonism (CI > 1). Additionally, PDTX + PAA induced an expressive morphological change, a major change in lysosome membrane permeation and mitochondria membrane permeation, cell cycle blockage in G2/M, and phosphatidylserine exposure. The study highlights the successful use of pequi oil nanoemulsions as delivery systems for DTX and AA, which enhances their antitumor effects against breast cancer cells. This nanotechnological approach shows significant potential for the treatment of triple-negative breast cancer.

1 October 2016 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
RSRenata Oliveira Silva
Renata Oliveira Silva
AOAndressa Souza de Oliveira
Andressa Souza de Oliveira
LLLaís Flávia Nunes Lemes
Laís Flávia Nunes Lemes
LNLuciana de Camargo Nascente
Luciana de Camargo Nascente
PNPatrícia Coelho Do Nascimento Nogueira
Patrícia Coelho Do Nascimento Nogueira
LRLuiz Romeiro
Luiz Romeiro